

Extending duration of letermovir prophylaxis in haploidentical stem cell transplantation

Authors

Pongthep Vittayawacharin,^{1,2} Benjamin J. Lee,^{3,4} Shawn Griffin,^{3,4} Jean Doh,^{3,4} Julie Smith,¹ Hannah Nam,⁵ Emily Blodget,⁵ Deepa Jeyakumar,¹ Piyanuch Kongtim¹ and Stefan O. Ciurea¹

¹Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, University of California Irvine, Irvine, CA, USA; ²Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; ³Department of


Pharmacy, University of California Irvine Health, Orange, CA, USA; ⁴Department of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, CA, USA and ⁵Division of Infectious Diseases, Department of Medicine, University of California Irvine, CA, USA

Correspondence:

S.O. CIUREA - sciurea@hs.uci.edu

<https://doi.org/10.3324/haematol.2024.285766>

Supplementary Figure 1: Cumulative incidence of letermovir discontinuation



Supplementary Figure 2. (2A) Non-relapse mortality, (2B) Relapse, (2C) Progression-free survival, (2D) Overall survival, (2E) Acute GVHD, (2F) Chronic GVHD

Abbreviation: CI: confidence interval, CS-CMVi: clinically significant cytomegalovirus infection, GVHD: graft-versus-host disease, HR hazard ratio, SHR subdistribution hazard ratio

